id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-311697-2w9qody4	Liu, Xi	Efficacy of chloroquine versus lopinavir/ritonavir in mild/general COVID-19 infection: a prospective, open-label, multicenter, randomized controlled clinical study	2020-07-08		.txt	text/plain	3933	210	52	title: Efficacy of chloroquine versus lopinavir/ritonavir in mild/general COVID-19 infection: a prospective, open-label, multicenter, randomized controlled clinical study Remdesivir (GS-5734) and chloroquine (Sigma-C6628) can effectively inhibit SARS-CoV-2 infection [17] This study will compare the efficacy, safety, and impact on patient compliance between the chloroquine phosphate regimen with the lopinavir/ritonavir regimen in mild/general COVID-19 infection. The PP group will include participants who satisfy the following conditions among the ITT group: (1) those who completed all planned visits and (2) those who did not receive and use drugs or treatments that may affect the evaluation of efficacy during the study. For the primary outcome of this trial, the clinical recovery time of no more than 28 days after the completion of therapy and follow-up will be estimated as the proportion with a 95% confidence interval (CI) for each treatment group. The purpose of this prospective, open-label, multicenter randomized controlled, comprehensive clinical study is to evaluate the efficacy and safety of chloroquine phosphate and lopinavir/ritonavir in patients with mild/general COVID-19 infection.	./cache/cord-311697-2w9qody4.txt	./txt/cord-311697-2w9qody4.txt